Sotera Health Company ( (SHC) ) has released its Q2 earnings. Here is a breakdown of the information Sotera Health Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sotera Health Company is a leading global provider specializing in sterilization solutions, lab testing, and advisory services for the healthcare industry, operating through its three businesses: Sterigenics, Nordion, and Nelson Labs.
Sotera Health reported strong financial results for the second quarter and first half of 2025, with notable increases in net revenues and adjusted EBITDA. The company has raised its full-year outlook, reflecting confidence in its continued performance.
In the second quarter of 2025, Sotera Health’s net revenues rose by 6.4% to $294 million, while adjusted EBITDA increased by 9.8% to $151 million. The company also reported an adjusted EPS of $0.20, up from $0.19 in the previous year. The Sterigenics segment showed significant growth, with a 10.5% increase in net revenues, driven by favorable volume and pricing. Meanwhile, Nordion and Nelson Labs experienced mixed results, with Nordion showing revenue growth and Nelson Labs facing a decline.
For the first half of 2025, net revenues increased by 4.6% to $549 million, and adjusted EBITDA grew by 9.3% to $273 million. Despite a net loss of $5 million due to litigation settlements, the company remains optimistic, raising its full-year revenue growth outlook to 4.5%-6.0% and adjusted EBITDA growth to 6.0%-7.5%.
Looking ahead, Sotera Health’s management is optimistic about the company’s performance, with expectations of continued growth and execution. The company has updated its financial outlook, anticipating stable foreign currency impacts and maintaining a strong position in the healthcare industry.